Veloxis Pharmaceuticals’ $46 Million Kickback Settlement: A CEP Case Study Worth Studying Closely
Veloxis Pharmaceuticals, the maker of the kidney transplant immunosuppression drug Envarsus XR, has agreed to pay more than $46 million and submit to years of enhanced compliance oversight to resolve civil and criminal allegations that the company ran a sustained kickback scheme to drive prescriptions of its drug. This case is worth a close read for compliance officers well beyond the pharmaceutical industry, because it’s...











